Anacor regains anti-fungal drug rights from Merck

Merck has handed back rights to Anacor Pharmaceuticals' anti-fungal treatment, AN2690. Anacor inked an agreement with Schering-Plough in 2007 for rights to the treatment, and Merck acquired those rights after its buyout of Schering. Anacor says it will launch a late-stage trial of the drug while it looks for a new partner. Anacor release | Article

Suggested Articles

Canadian biotech AbCellera has nabbed a meaty $105 million series B funding round as it looks to boost its antibody work and seek out new potential me

Q32 Bio is working on treatments for autoimmune and inflammatory diseases that improve on systemic approaches.

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.